Hexiris Strengthens Leadership with New Board Members
Hexiris Inc., a prominent name in the R&D medtech sector, is excited to announce the appointments of Paul Sowyrda and Steven Schiffman to its Board of Directors. This strategic move aims to enhance its mission of providing innovative ophthalmic solutions that cater to patients and ophthalmologists alike.
The Vision Behind Hexiris
Founded with a vision to revolutionize ophthalmic care, Hexiris is dedicated to developing advanced medical technologies that improve treatment accessibility. The inclusion of two industry veterans to its board signifies a robust commitment to expanding its footprint in the healthcare sector.
Meet Paul Sowyrda: A Leader in Life Sciences
Paul Sowyrda brings over 25 years of rich experience in the life sciences industry to the board. As the co-founder of Novellus, Inc., he played a crucial role until its acquisition. His expertise spans drugs and medical devices, marking him as a forward-thinking leader in the field. Currently, he serves as Vice President of Business Development at Citius Pharmaceuticals and holds multiple patents, underscoring his innovative mindset.
Introducing Steven Schiffman: A Financial Executive's Perspective
Steven Schiffman adds a wealth of experience with his extensive background in finance and private equity. Having recently retired as CFO of Devonshire Investors, he is well-versed in managing financial operations for large-scale organizations. His knowledge will undoubtedly aid Hexiris in strategic fiscal decisions as it progresses towards its growth objectives.
Why These Appointments Matter
The appointments of Sowyrda and Schiffman are more than just additions to the board; they bring invaluable insights and perspectives that align with Hexiris's mission. According to Houfar Sekhavat, Co-Founder and Co-CEO, their expertise in strategic foresight and investment strategies will be pivotal in navigating the future landscape of ophthalmology. Their experience will enhance Hexiris's ability to innovate and address unmet needs within the industry.
Innovative Developments and Product Launches
Hexiris is on the cutting edge of developing medical devices aimed at transforming ophthalmic treatment. One of their most noteworthy projects is the Advanced Technology Device designed for Minimally Invasive Glaucoma Surgeries (MIGS). This game-changing device has the potential to make glaucoma treatment not only more straightforward but also more accessible for various practitioners.
More about the Hexiris MIGS Solution
The Hexiris MIGS Solution features a patented ocular implant, a first-of-its-kind injectable implant that can be used in standard office settings, reducing the need for extensive surgical setups. It's set to change the paradigm of glaucoma treatments by enabling certified ophthalmologists to perform outpatient procedures, thus improving patient experiences and outcomes.
Cost-Effective Treatment Pathways
As healthcare costs continue to rise, the Hexiris MIGS Solution offers a comprehensive and economical approach to treating glaucoma. By streamlining procedures, it not only promises improved patient outcomes but also alleviates some of the financial pressures on healthcare systems, especially with an aging population that requires such services.
A Look Ahead for Hexiris
With the recent strategic appointments and the ongoing development of pioneering products, Hexiris is poised to take significant steps in the medtech space and reshape the future of ophthalmology. For those interested in staying updated on their journey and innovations, further information can be accessed through their official channels.
Frequently Asked Questions
Who are the new board members at Hexiris?
Paul Sowyrda and Steven Schiffman are the newly appointed members of Hexiris's Board of Directors.
What is the role of Paul Sowyrda in Hexiris?
Paul Sowyrda will leverage his extensive experience to guide strategic growth initiatives at Hexiris.
What industry experience does Steven Schiffman bring?
Steven Schiffman has over 35 years of experience in finance, private equity, and corporate leadership.
What innovative product is Hexiris developing?
Hexiris is creating a groundbreaking ocular implant for Minimally Invasive Glaucoma Surgeries.
How does the Hexiris MIGS solution enhance treatment accessibility?
The MIGS solution enables outpatient procedures, making glaucoma treatment simpler and more cost-effective.
